Daniela Zackova (Daniela Žáčková)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 26

Top Venues

Leukemia

American journal of hematology

Blood advances

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Daniela Zackova, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková, Petra Čičátková, Anežka Kvetková, Tomas Hornak, Ivana Skoumalová, Dana Srbová, Cyril Salek, David Buffa, Jaroslava Voglová, Tomáš Jurček, Adam Folta, Ivana Ježíšková, Hana Žižková, Kateřina Machová Poláková, Tomáš Papajík, Pavel Žák, Pavel Jindra, Adam Svobodník, Radka Štěpánová, Jiří Mayer
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia 38 (4) (2024)
Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck E Nicolini, Jiri Mayer, Daniela Zackova, Jeroen J W M Janssen, Panayiotis Panayiotidis, Hanne Vestergaard, Perttu Koskenvesa, Antonio Almeida, Henrik Hjorth-Hansen, Joaquin Martinez-Lopez, Ulla Olsson-Strömberg, Andreas Hochhaus, Marc G Berger, Gabriel Etienne, Hana Klamova, Edgar Faber, Philippe Rousselot, Markus Pfirrmann, Susanne Saussele
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. Leukemia (2024)
Tomas Hornak, Jiri Mayer, Petra Cicatkova, Lukas Semerad, Anezka Kvetkova, Hana Klamova, Edgar Faber, Petra Belohlavkova, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Dana Srbova, Hana Zizkova, Lucia Vrablova, Ivana Skoumalova, Jaroslava Voglova, Tereza Jurkova, Marika Chrapava, Tomas Jurcek, Ivana Jeziskova, Marie Jarosova, Katerina Machova Polakova, Tomas Papajik, Pavel Zak, Pavel Jindra, Daniela Zackova
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. American journal of hematology (2024)
Maria Agustina Perusini, Daniela Zackova, TaeHyung Kim, Katia B B Pagnano, Carolina Pavlovsky, Ivana Ježíšková, Anežka Kvetková, Tomas Jurcek, Jaeyoon John Kim, Young Seok Yoo, Seongyoon Yi, Hyewon Lee, Kyoung Ha Kim, Myunghee Chang, Jose-Mario Capo-Chichi, Jessie J F Medeiros, Andrea Arruda, Mark D Minden, Zhaolei Zhang, Sagi Abelson, Jiri Mayer, Dennis Dong Hwan Kim
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes. Blood advances (2024)
Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck E Nicolini, Jiri Mayer, Daniela Zackova, Jeroen J W M Janssen, Panayiotis Panayiotidis, Hanne Vestergaard, Perttu Koskenvesa, Antonio Almeida, Henrik Hjorth-Hansen, Joaquin Martinez-Lopez, Ulla Olsson-Strömberg, Andreas Hochhaus, Marc G Berger, Gabriel Etienne, Hana Klamova, Edgar Faber, Philippe Rousselot, Markus Pfirrmann, Susanne Saussele
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. Leukemia 38 (8) (2024)
Daniela Zackova, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková, Petra Čičátková, Anežka Kvetková, Tomas Hornak, Ivana Skoumalová, Dana Srbová, Cyril Salek, David Buffa, Jaroslava Voglová, Tomáš Jurček, Adam Folta, Ivana Ježíšková, Hana Žižková, Kateřina Machová Poláková, Tomáš Papajík, Pavel Žák, Pavel Jindra, Adam Svobodník, Radka Štěpánová, Jiří Mayer
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia 38 (4) (2024)
Daniela Zackova, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková, Petra Čičátková, Anežka Kvetková, Tomas Hornak, Ivana Skoumalová, Dana Srbová, Cyril Salek, David Buffa, Jaroslava Voglová, Tomáš Jurček, Adam Folta, Ivana Ježíšková, Hana Žižková, Kateřina Machová Poláková, Tomáš Papajík, Pavel Žák, Pavel Jindra, Adam Svobodník, Radka Štěpánová, Jiří Mayer
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia 38 (4) (2024)
Tomas Hornak, Jiri Mayer, Petra Cicatkova, Lukas Semerad, Anezka Kvetkova, Hana Klamova, Edgar Faber, Petra Belohlavkova, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Dana Srbova, Hana Zizkova, Lucia Vrablova, Ivana Skoumalova, Jaroslava Voglova, Tereza Jurkova, Marika Chrapava, Tomas Jurcek, Ivana Jeziskova, Marie Jarosova, Katerina Machova Polakova, Tomas Papajik, Pavel Zak, Pavel Jindra, Daniela Zackova
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. American journal of hematology 99 (4) (2024)
Daniela Zackova, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková, Petra Čičátková, Anežka Kvetková, Tomas Hornak, Ivana Skoumalová, Dana Srbová, Cyril Salek, David Buffa, Jaroslava Voglová, Tomáš Jurček, Adam Folta, Ivana Ježíšková, Hana Žižková, Kateřina Machová Poláková, Tomáš Papajík, Pavel Žák, Pavel Jindra, Adam Svobodník, Radka Štěpánová, Jiří Mayer
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia (2024)
Petra Belohlavkova, Daniela Zackova, Hana Klamova, Edgar Faber, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Ivana Jeziskova, Katerina Machova Polakova, Pavel Zak, Tereza Jurkova, Marika Chrapava, Jiri Mayer
Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data. Cancer medicine 13 (17) (2024)
Maria Agustina Perusini, Daniela Zackova, Taehyung Kim, Katia B B Pagnano, Carolina Pavlovsky, Ivana Ježíšková, Anežka Kvetková, Tomáš Jurček, Jaeyoon Kim, Youngseok Yoo, Seongyoon Yi, Hyewon Lee, Kyoung Ha Kim, Myunghee Chang, Jose-Mario Capo-Chichi, Jessie J F Medeiros, Andrea Arruda, Mark D Minden, Zhaolei Zhang, Sagi Abelson, Jiri Mayer, Dennis Dong Hwan Kim
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes. Blood advances 8 (10) (2024)
Daniela Zackova, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková, Petra Čičátková, Anežka Kvetková, Tomas Hornak, Ivana Skoumalová, Dana Srbová, Cyril Salek, David Buffa, Jaroslava Voglová, Tomáš Jurček, Adam Folta, Ivana Ježíšková, Hana Žižková, Kateřina Machová Poláková, Tomáš Papajík, Pavel Žák, Pavel Jindra, Adam Svobodník, Radka Štěpánová, Jiří Mayer
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia 38 (4) (2024)
Daniela Zackova, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková, Petra Čičátková, Anežka Kvetková, Tomas Hornak, Ivana Skoumalová, Dana Srbová, Cyril Salek, David Buffa, Jaroslava Voglová, Tomáš Jurček, Adam Folta, Ivana Ježíšková, Hana Žižková, Kateřina Machová Poláková, Tomáš Papajík, Pavel Žák, Pavel Jindra, Adam Svobodník, Radka Štěpánová, Jiří Mayer
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia 38 (4) (2024)
Maria Agustina Perusini, Daniela Zackova, Taehyung Kim, Katia B B Pagnano, Carolina Pavlovsky, Ivana Ježíšková, Anežka Kvetková, Tomáš Jurček, Jaeyoon Kim, Youngseok Yoo, Seongyoon Yi, Hyewon Lee, Kyoung Ha Kim, Myunghee Chang, Jose-Mario Capo-Chichi, Jessie J F Medeiros, Andrea Arruda, Mark D Minden, Zhaolei Zhang, Sagi Abelson, Jiri Mayer, Dennis Dong Hwan Kim
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes. Blood advances 8 (10) (2024)
Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck E Nicolini, Jiri Mayer, Daniela Zackova, Jeroen J W M Janssen, Panayiotis Panayiotidis, Hanne Vestergaard, Perttu Koskenvesa, Antonio Almeida, Henrik Hjorth-Hansen, Joaquin Martinez-Lopez, Ulla Olsson-Strömberg, Andreas Hochhaus, Marc G Berger, Gabriel Etienne, Hana Klamova, Edgar Faber, Philippe Rousselot, Markus Pfirrmann, Susanne Saussele
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. Leukemia 38 (8) (2024)
Tomas Hornak, Jiri Mayer, Petra Cicatkova, Lukas Semerad, Anezka Kvetkova, Hana Klamova, Edgar Faber, Petra Belohlavkova, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Dana Srbova, Hana Zizkova, Lucia Vrablova, Ivana Skoumalova, Jaroslava Voglova, Tereza Jurkova, Marika Chrapava, Tomas Jurcek, Ivana Jeziskova, Marie Jarosova, Katerina Machova Polakova, Tomas Papajik, Pavel Zak, Pavel Jindra, Daniela Zackova
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. American journal of hematology 99 (4) (2024)
Tomas Hornak, Jiri Mayer, Petra Cicatkova, Lukas Semerad, Anezka Kvetkova, Hana Klamova, Edgar Faber, Petra Belohlavkova, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Dana Srbova, Hana Zizkova, Lucia Vrablova, Ivana Skoumalova, Jaroslava Voglova, Tereza Jurkova, Marika Chrapava, Tomas Jurcek, Ivana Jeziskova, Marie Jarosova, Katerina Machova Polakova, Tomas Papajik, Pavel Zak, Pavel Jindra, Daniela Zackova
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. American journal of hematology 99 (4) (2024)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38 (2) (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38 (2) (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38 (2) (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38 (2) (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38 (2) (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38 (2) (2023)
Andrea Knight, Martin Piskacek, Michal Jurajda, Jirina Prochazkova, Zdenek Racil, Daniela Zackova, Jiri Mayer
Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia. Cancer immunology, immunotherapy : CII (2022)
Adam Folta, Tomas Jurcek, Blanka Kubesova, Daniela Zackova, Lukas Semerad, Jiří Mayer, Ivana Ježíšková
Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients. Leukemia & lymphoma 62 (5) (2020)

Daniela Zackova.css-eqlu8i{font-size:small;padding-left:4px;} (Daniela Žáčková)

Publication Activity (10 Years)

Top Topics

Top Venues

Daniela Zackova (Daniela Žáčková)